<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673777</url>
  </required_header>
  <id_info>
    <org_study_id>IMS-NSCLC02</org_study_id>
    <nct_id>NCT00673777</nct_id>
  </id_info>
  <brief_title>Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201
      restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      URLC10 has been identified as cancer specific molecules especially in non small cell lung
      cancer using genome-wide expression profile analysis by cDNA microarray technique. We have
      determined the HLA-A*0201 restricted epitope peptides derived from these molecules. We also
      tend to use the peptides targeting to tumor angiogenesis. VEGF receptor 1 and 2 are essential
      targets to tumor angiogenesis, and we identified that peptides derived from these receptors
      significantly induce the effective tumor specific CTL response in vitro and vivo. According
      to these findings, in this trial, we evaluate the safety, immunological and clinical response
      of those peptides. Patients will be vaccinated twice a week for 8 weeks. On each vaccination
      day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with
      Montanide ISA 51 will be administered by subcutaneous injection. Repeated cycles of vaccine
      will be administered until patients develop progressive disease or unacceptable toxicity,
      whichever occurs first. In the phase I study, we evaluate the safety and tolerability of
      these peptide vaccine. In the following phase II study, we evaluate the immunological and
      clinical response of this vaccine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)</measure>
    <time_frame>two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunological responses</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>one years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>URLC10, VEGFR1 and VEGFR2</intervention_name>
    <description>Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease characteristics

          -  Advanced or recurrent non small cell lung cancer

          -  Second line or later therapeutic status Patient characteristics

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  HLA-A*0201

          -  Laboratory values as follows

               -  2000/mm3&lt;WBC&lt;15000/mm3

               -  Platelet count&gt;100000/mm3

               -  Bilirubin &lt; 3.0mg/dl

               -  Asparate transaminase &lt; 150IU/L

               -  Alanine transaminase &lt; 150IU/L

               -  Creatinine &lt; 3.0mg/dl

          -  Able and willing to give valid written informed consent

        Exclusion Criteria:

          -  Pregnancy(woman of childbearing potential:Refusal or inability to use effective means
             of contraception)

          -  Breastfeeding

          -  Active or uncontrolled infection

          -  Unhealed external wound

          -  Concurrent treatment with steroids or immunosuppressing agent

          -  Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks

          -  Uncontrolled brain and/or intraspinal metastasis

          -  Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naohida Yamashita, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokyo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeshi Fujii, MD/PhD</last_name>
    <phone>81-3-3443-8111</phone>
    <phone_ext>75032</phone_ext>
    <email>tmks@ims.u-tokyo.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Institute of Medical Science, The University of Tokyo</name>
      <address>
        <city>Tokyo</city>
        <zip>108-8639</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Fujii, MD/PhD</last_name>
      <phone>81-3-3443-8111</phone>
      <phone_ext>75032</phone_ext>
      <email>tmks@ims.u-tokyo.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Fujii, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May;97(5):411-9.</citation>
    <PMID>16630140</PMID>
  </reference>
  <reference>
    <citation>Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):43-53. doi: 10.1007/s11748-007-0211-x. Epub 2008 Feb 24. Review.</citation>
    <PMID>18297458</PMID>
  </reference>
  <reference>
    <citation>Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov;98(11):1803-8.</citation>
    <PMID>17784873</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <reference>
    <citation>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.</citation>
    <PMID>12415261</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>May 12, 2008</last_update_submitted>
  <last_update_submitted_qc>May 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Department of Infectious Disease and Applied Immunology</name_title>
    <organization>The Institute of Medical Science, The University of Tokyo</organization>
  </responsible_party>
  <keyword>HLA-A*0201</keyword>
  <keyword>Peptide Vaccine</keyword>
  <keyword>URLC10</keyword>
  <keyword>VEGFR1</keyword>
  <keyword>VEGFR2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

